Literature DB >> 8348381

Combined treatment with calcitonin and 1,25-dihydroxyvitamin D3 for osteoporosis in women.

S A Eriksson1, J U Lindgren.   

Abstract

Twenty-two middle-aged women with severe osteoporosis were treated for 2 years with either 0.5 mg of synthetic human calcitonin subcutaneously three times per week combined with 0.5 micrograms of calcitriol and 0.5 g of calcium per day orally or calcium only. The treatment with calcitonin plus calcitriol (12 patients) resulted in a significantly increased calcium absorption rate. The mean values for serum phosphate did not change during the treatment period and the mean values did not differ between the treatment groups, but the serum calcium and urinary Ca/Cr ratio increased somewhat in the group given the combined treatment. There was no evidence that the combined treatment improved the bone density in this study. It is possible that calcitriol, instead of increasing the effect of calcitonin by suppression of the parathyroid, might have counteracted its effect by increasing the bone resorption.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348381     DOI: 10.1007/bf01352011

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  8 in total

1.  Treatment of postmenopausal osteoporosis with calcitriol or calcium.

Authors:  M W Tilyard; G F Spears; J Thomson; S Dovey
Journal:  N Engl J Med       Date:  1992-02-06       Impact factor: 91.245

2.  Calcitriol treatment is not effective in postmenopausal osteoporosis.

Authors:  S M Ott; C H Chesnut
Journal:  Ann Intern Med       Date:  1989-02-15       Impact factor: 25.391

3.  Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene.

Authors:  J Russell; D Lettieri; L M Sherwood
Journal:  Endocrinology       Date:  1986-12       Impact factor: 4.736

4.  Does 1,25(OH)2D3 accelerate spinal bone loss? A controlled therapeutic trial in 70-year-old women.

Authors:  G F Jensen; B Meinecke; J Boesen; I Transbøl
Journal:  Clin Orthop Relat Res       Date:  1985 Jan-Feb       Impact factor: 4.176

5.  Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.

Authors:  R Civitelli; S Gonnelli; F Zacchei; S Bigazzi; A Vattimo; L V Avioli; C Gennari
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

6.  1,25-Dihydroxyvitamin D3: short- and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis.

Authors:  J C Gallagher; C M Jerpbak; W S Jee; K A Johnson; H F DeLuca; B L Riggs
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

7.  Calcitriol in the treatment of postmenopausal osteoporosis.

Authors:  J F Aloia; A Vaswani; J K Yeh; K Ellis; S Yasumura; S H Cohn
Journal:  Am J Med       Date:  1988-03       Impact factor: 4.965

8.  1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin.

Authors:  J Y Reginster; D Denis; A Albert; R Deroisy; M P Lecart; M A Fontaine; P Lambelin; P Franchimont
Journal:  Lancet       Date:  1987-12-26       Impact factor: 79.321

  8 in total
  3 in total

1.  Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.

Authors:  Evangelia Kaskani; G P Lyritis; C Kosmidis; A Galanos; G Andypas; K Chorianopoulos; A Giagiosis; K Iliadou; A Karagianis; K Katsimichas; A Koskinas; K Matsouka
Journal:  Clin Rheumatol       Date:  2005-01-13       Impact factor: 2.980

Review 2.  The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review.

Authors:  L J Peppone; S Hebl; J Q Purnell; M E Reid; R N Rosier; K M Mustian; O G Palesh; A J Huston; M N Ling; G R Morrow
Journal:  Osteoporos Int       Date:  2009-12-04       Impact factor: 4.507

3.  Calcitonin and vitamin D3 have high therapeutic potential for improving diabetic mandibular growth.

Authors:  Mona A Abbassy; Ippei Watari; Ahmed S Bakry; Takashi Ono; Ali H Hassan
Journal:  Int J Oral Sci       Date:  2016-03-30       Impact factor: 6.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.